<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077284</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-67_201</org_study_id>
    <secondary_id>U1111-1113-6322</secondary_id>
    <nct_id>NCT01077284</nct_id>
  </id_info>
  <brief_title>Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of febuxostat, once daily (QD),
      compared to allopurinol or placebo in patients with excessive amounts of uric acid in their
      urine and who have recently had kidney stones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrolithiasis, also called kidney stone disease, occurs in patients with genetic
      susceptibility and who may have a broad spectrum of metabolic disorders and other comorbid
      conditions (for example obesity or diabetes). These renal stones develop as a result of
      supersaturation. Calcium oxalate (CaOx) is the most common type of stone. Reducing the
      urinary excretion of uric acid is an established approach for the treatment of CaOx kidney
      stones.

      The objective of this study is to evaluate treatment with febuxostat compared to allopurinol
      or placebo in the reduction of 24-hour urine uric acid (uUA) excretion levels in
      hyperuricosuric patients with a recent history of renal stones and the presence of at least
      one CaOx stone larger than or equal to 3 mm as seen on Multidetector Computed Tomographic
      Angiography (MDCT).

      Participants in this study will be required to make 4 office visits provide 3 urine samples
      and undergo 2 MDCT scans (a type of x-ray) of their kidneys.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader. The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in the Number of Calcium Oxalate Stones</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in 24-hour Measured Creatinine Clearance</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles. Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Hyperuricosuria</condition>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat capsules</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
    <other_name>TMX-67</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol capsules</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <other_name>Zyloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has hyperuricosuria, defined as a daily urine uric acid excretion greater than 700 mg
             as measured by 24-hour urine collection prior to randomization.

          -  Has at least one calcium oxalate stone greater than or equal to 3 mm in its longest
             in-plane diameter, identified by Multiple Detector Computated Tomography prior to
             randomization.

          -  Has a recent (within the previous 5 years) history of renal stones prior to
             screening.

        Exclusion Criteria:

          -  Has gout, secondary hyperuricemia or has experienced a gout flare.

          -  Has a history of xanthinuria.

          -  Has received allopurinol or probenecid within 2 years prior to randomization.

          -  Has received febuxostat.

          -  Has alanine aminotransferase and/or aspartate aminotransferase values greater than
             2.0 times the upper limit of normal at the Screening Visit.

          -  Has an abnormal serum calcium level at the Screening Visit.

          -  Has a significant medical condition and/or conditions that would interfere with the
             treatment, safety or compliance with the protocol according to the judgment of the
             Investigator.

          -  Has a history of drug abuse or a history of alcohol abuse within 5 years prior to the
             Screening Visit.

          -  Participant's measured creatinine clearance is less than 30 mL/min at the Screening
             Visit.

          -  Has hypercalciuria at Screening, while on a regular unrestricted diet, defined as
             urinary excretion of:

               -  greater than 250 mg of calcium/24-hour for females of body weight less than 62.5
                  kg; OR

               -  greater than 300 mg calcium/24-hour for males of body weight less than 75 kg; OR

               -  greater than 4 mg calcium/kg/24-hour for males of body weight greater than or
                  equal 75 kg and females of body weight greater than or equal 62.5 kg.

        EXCLUDED MEDICATIONS:

          -  Febuxostat, allopurinol, probenecid.

          -  Salicylates (chronic use of aspirin â‰¤325 mg/day is allowed).

          -  Azathioprine.

          -  Mercaptopurine.

          -  Theophylline.

          -  Colchicine.

          -  Pyrazinamide.

          -  Sulfamethoxazole/trimethoprim.

          -  Losartan.

        The following restrictions also apply during the study:

          -  Long-term use (more than 4 continuous weeks) of prescription or over-the-counter
             nonsterioidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors.

          -  If receiving diuretics, participant must have been on a stable dose for at least 30
             days prior to screening. No changes in dosage are allowed during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 14, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2010</firstreceived_date>
  <firstreceived_results_date>October 15, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Calculi</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Nephrolithiasis</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Uric Acid</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 24 investigative sites in the United States from 12 February 2010 to 21 November 2011.</recruitment_details>
      <pre_assignment_details>Participants with hyperuricosuria and calcium oxalate stones were randomized to 1 of 3 treatment groups in a 1:1:1 ratio to receive placebo, allopurinol or febuxostat.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat</title>
          <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Allopurinol</title>
          <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat</title>
          <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Allopurinol</title>
          <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.1" spread="9.69"/>
                <measurement group_id="B2" value="46.5" spread="9.95"/>
                <measurement group_id="B3" value="46.5" spread="11.54"/>
                <measurement group_id="B4" value="47.4" spread="10.39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="85"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-Hispanic and Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="29"/>
                <measurement group_id="B4" value="86"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="172.6" spread="12.67"/>
                <measurement group_id="B2" value="176.5" spread="7.71"/>
                <measurement group_id="B3" value="174.3" spread="9.31"/>
                <measurement group_id="B4" value="174.5" spread="10.14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="98.0" spread="18.17"/>
                <measurement group_id="B2" value="100.9" spread="20.13"/>
                <measurement group_id="B3" value="100.8" spread="20.23"/>
                <measurement group_id="B4" value="99.9" spread="19.38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.9" spread="5.71"/>
                <measurement group_id="B2" value="32.3" spread="5.82"/>
                <measurement group_id="B3" value="33.1" spread="6.29"/>
                <measurement group_id="B4" value="32.8" spread="5.89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body mass index categories</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18.5 to &lt;25 kg/m^2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>25 to &lt;30 kg/m^2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>â‰¥30 kg/m^2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="24"/>
                <measurement group_id="B4" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline Serum Urate</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6.2" spread="1.63"/>
                <measurement group_id="B2" value="6.3" spread="1.49"/>
                <measurement group_id="B3" value="6.3" spread="1.24"/>
                <measurement group_id="B4" value="6.3" spread="1.45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline Serum Urate categories</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;9.0 mg/dL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="32"/>
                <measurement group_id="B4" value="94"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>9.0 to &lt;10 mg/dL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>â‰¥10 mg/dL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Renal history</title>
          <description>Moderately impaired = measured creatinine clearance (mCLcr) 30-59 mL/min, mildly impaired = mCLcr 60-89 mL/min, and normal = mCLcr â‰¥90 mL/min.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Moderately impaired</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mildly impaired</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Normal</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="32"/>
                <measurement group_id="B4" value="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>24-hour urine uric acid</title>
          <units>mg/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1000.6" spread="223.99"/>
                <measurement group_id="B2" value="948.1" spread="231.16"/>
                <measurement group_id="B3" value="909.4" spread="166.43"/>
                <measurement group_id="B4" value="952.7" spread="210.44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>24-hour urine uric acid categories</title>
          <description>Categories are based on tertiles, T1: 33.3rd percentile and T2: 66.6th percentile.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>â‰¤820 mg/24 hours (T1)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;820 to â‰¤987 mg/24 hours</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;987 mg/24 hours (T2)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>24-hour urinary calcium</title>
          <units>mg/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="240.1" spread="84.08"/>
                <measurement group_id="B2" value="297.9" spread="77.60"/>
                <measurement group_id="B3" value="278.7" spread="99.62"/>
                <measurement group_id="B4" value="272.2" spread="90.00"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Lifetime kidney stone episodes</title>
          <units>kidney stone episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.8" spread="10.18"/>
                <measurement group_id="B2" value="12.5" spread="19.72"/>
                <measurement group_id="B3" value="11.3" spread="14.97"/>
                <measurement group_id="B4" value="10.9" spread="15.38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Kidney stone passage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>No</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Yes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="29"/>
                <measurement group_id="B4" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Composition of most recent passed stone</title>
          <description>Includes participants with a kidney stone passage: 27, 33 and 29 participants for each treatment group, respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Calcium Oxalate</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Uric acid</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Calcium citrate</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="52"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Kidney stone procedures</title>
          <description>Participants may have had more than one kidney stone procedure.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>None</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Shock Wave Lithotripsy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ureteroscopy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Nephrolithotomy/Nephrolithotripsy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Open surgery</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other procedure</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stone Procedure</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Use of kidney stone drug</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>None</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="88"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Allopurinol</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other drug therapy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline in-plane Diameter of the largest Calcium Oxalate Stone</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12.24" spread="7.363"/>
                <measurement group_id="B2" value="9.34" spread="4.311"/>
                <measurement group_id="B3" value="8.22" spread="3.756"/>
                <measurement group_id="B4" value="9.91" spread="5.590"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion</title>
        <description>The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The full analysis set (patients who took at least 1 dose of double-blind study drug and had a baseline 24-hour uUA &gt;700 mg and at least 1 kidney CaOx stone â‰¥3 mm in its longest inplane diameter). Missing Month 6 values were imputed with baseline values if patient discontinued due to an AE; or otherwise with the last available post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion</title>
            <description>The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-58.6" spread="28.56"/>
                  <measurement group_id="O2" value="-36.4" spread="36.97"/>
                  <measurement group_id="O3" value="-12.7" spread="28.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hochbergâ€™s method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.003</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone</title>
        <description>Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader. The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set, for whom Baseline and Month 6 MDCT data were available. Measurements more than 1-day after a patient's last dose of study drug were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone</title>
            <description>Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader. The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-6.50" spread="28.357"/>
                  <measurement group_id="O2" value="0.63" spread="12.605"/>
                  <measurement group_id="O3" value="3.20" spread="23.697"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.130</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.348</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in the Number of Calcium Oxalate Stones</title>
        <description>Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set for whom both Baseline and Month 6 MDCT data were available. Measurements more than 1 day after a patientâ€™s last dose of study drug were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in the Number of Calcium Oxalate Stones</title>
            <description>Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader.</description>
            <units>stones</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (n=28, 24, 30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.84" spread="3.921"/>
                  <measurement group_id="O2" value="6.60" spread="6.832"/>
                  <measurement group_id="O3" value="5.57" spread="5.785"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline (n=26, 23, 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.06" spread="1.602"/>
                  <measurement group_id="O2" value="0.28" spread="1.953"/>
                  <measurement group_id="O3" value="0.10" spread="1.817"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.403</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.413</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in 24-hour Measured Creatinine Clearance</title>
        <description>Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles. Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set. Missing Month 6 Visit 24-hour mCLcr values are imputed by Month 3 values if the Month 3 value was available otherwise the patient was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in 24-hour Measured Creatinine Clearance</title>
            <description>Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles. Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).</description>
            <units>mL/min/1.73mÂ²</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (n=33, 33, 33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="146.9" spread="57.88"/>
                  <measurement group_id="O2" value="146.0" spread="44.32"/>
                  <measurement group_id="O3" value="147.1" spread="53.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline (n=30, 29, 30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.0" spread="60.82"/>
                  <measurement group_id="O2" value="-7.7" spread="83.28"/>
                  <measurement group_id="O3" value="-19.0" spread="45.72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5535</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>P-values are from ANOVA with treatment as a fixed effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9400</p_value>
            <p_value_desc>Hochberg's method for multiple comparisons was used to ensure that the overall 0.050 level of significance was maintained for comparisons of febuxostat to allopurinol and to placebo.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>P-values are from ANOVA with treatment as a fixed effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent AEs were defined as any AE, regardless of relationship to study drug, which occurred on or after the first double blind dose date and up to 30 days after the last dose date of the double-blind study drug (up to 7 months).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat</title>
          <description>Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Allopurinol</title>
          <description>Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Creatinine urine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Urine calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
